Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019

Published by Global Markets Direct on 11th November 2019 | Ref: 1463976 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 6, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).

- The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acute Respiratory Distress Syndrome - Overview

Acute Respiratory Distress Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Respiratory Distress Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Respiratory Distress Syndrome - Companies Involved in Therapeutics Development

Athersys Inc

Bayer AG

Cells for Cells SA

Commence Bio Inc

CompleGen Inc

Cynata Therapeutics Ltd

Emergent BioSolutions Inc

Faron Pharmaceuticals Oy

Hydra Biosciences Inc

Liminal BioSciences Inc

Meridigen Biotech Co Ltd

Northern Therapeutics Inc

Savara Inc

SolAeroMed Inc

Windtree Therapeutics Inc

Acute Respiratory Distress Syndrome - Drug Profiles

Aerosurf - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CGX-1037 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enamptcumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Acute Respiratory Distress Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HC-067047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-14 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imatinib mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon beta-1a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IO-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSC-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Multistem - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAV-5093 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide for Acute Respiratory Distress Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plasminogen (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXVX-0047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-1229 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

simvastatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Soluble Guanylate Cyclase for Acute Respiratory Distress Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Sphingosine 1-Phosphate Receptor for Acute Respiratory Distress Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome and Sepsis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TCP-25 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMC-11912 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acute Respiratory Distress Syndrome - Dormant Projects

Acute Respiratory Distress Syndrome - Discontinued Products

Acute Respiratory Distress Syndrome - Product Development Milestones

Featured News & Press Releases

Oct 02, 2019: Faron Pharmaceuticals announces update on Traumakine drug substance manufacturing

Aug 20, 2019: Aqualung Therapeutics receives 5 thousand dollar National Institute of Health (NIH) grant to establish biomarker panel for patients with acute respiratory distress syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1463976 | GMDHC11411IDB

Number of Pages

123

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
22-03-2017

$2,000 USD

Published by Global Markets Direct
08-03-2017

$2,000 USD

Published by Timetric
01-03-2017

$75 USD

Published by Global Markets Direct
28-02-2017

$2,000 USD

Published by Global Data
22-02-2017

$2,500 USD

Published by Global Markets Direct
30-12-2016

$2,000 USD

Published by Global Markets Direct
30-11-2016

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.